申请人:KYOWA HAKKO KOGYO CO., LTD.
公开号:EP0565377A1
公开(公告)日:1993-10-13
Disclosed are therapeutic agents for use in the treatment of Parkinson's disease, such agents being xanthine derivatives of the Formula (I) and their pharmaceutical acceptable salts :
where R1, R2 and R3 are each H, C1-C6 alkyl or allyl ; and R4 is cycloalkyl of 3 to 8 carbon atoms, a -(CH2)n-R5 group where n is an cycloalkyl of 3 to 8 carbon atoms, a - (CH2)n-R5 group where n is an integer of from 0-4 and R5 is an aryl group of 6 to 10 carbon atoms or a heterocyclic group, such aryl or heterocyclic group optionally being substituted by up to 3 substituent(s) selected from C1-C6 alkyl, hydroxy, C1-C6 alkoxy, halogen, nitro and amino ; or
a
group, where Y1 and Y2 are each H or CH3 and Z is a substituted or unsubstituted aryl or heterocyclic group as defined under R5.
本发明揭示了治疗帕金森病的治疗剂,该治疗剂为公式(I)的黄嘌呤衍生物及其药物可接受的盐:其中,R1、R2和R3分别为H、C1-C6烷基或丙烯基;而R4为3至8个碳原子的环烷基,-(CH2)n-R5基团,其中n为3至8个碳原子的环烷基,-(CH2)n-R5基团,其中n为0-4的整数,而R5为6至10个碳原子的芳基基团或杂环基团,所述芳基或杂环基团可选地被选自C1-C6烷基,羟基,C1-C6烷氧基,卤素,硝基和氨基的最多3个取代基所取代;或Y1和Y2分别为H或CH3,而Z为根据R5所定义的取代或未取代的芳基或杂环基团的一个基团。